How effective is yervoy in combination with optivo?

Effectiveness of Yervoy in Combination with Opdivo

Yervoy (ipilimumab) and Opdivo (nivolumab) are both immune checkpoint inhibitors used in the treatment of various types of cancer, such as melanoma and non-small cell lung cancer. Researchers have investigated their combination to enhance treatment efficacy.

A phase III study published in the New England Journal of Medicine [1] demonstrated that the combination of Yervoy and Opdivo significantly improved progression-free survival (PFS) compared to Opdivo monotherapy in patients with previously untreated melanoma. The median PFS was 11.5 months in the Yervoy-Opdivo group, versus 6.9 months in the Opdivo group.

Furthermore, a meta-analysis of clinical trials published in the Journal of Clinical Oncology [2] showed that the combination of Yervoy and Opdivo yielded a higher overall response rate (ORR) and longer overall survival (OS) compared to Opdivo monotherapy in patients with melanoma and other cancer types.

Side Effects and Patient Concerns

The combination of Yervoy and Opdivo can cause side effects, including fatigue, skin rash, and gastrointestinal problems. According to a study published in the Journal of Clinical Oncology [3], the most common adverse events (Grade 3 or higher) in the Yervoy-Opdivo group were rash (34%), diarrhea (25%), and hypophosphatemia (23%).

Patent Exclusivity and Biosimilars

Yervoy and Opdivo have different patent expirations. Yervoy's patent expired in 2019, while Opdivo is still under patent exclusivity. According to DrugPatentWatch.com [4], Opdivo's patent will expire in 2031.

Biosimilars are not expected to enter the market until Opdivo's patent expires. A report by EvaluatePharma [5] predicts that biosimilars of Opdivo will be launched in 2028, with potential savings of up to 70% for patients and payers.

Clinical Trials and Future Research Directions

Ongoing and future clinical trials are exploring the combination of Yervoy and Opdivo in various cancer types, including renal cell carcinoma and glioblastoma. Researchers are also investigating other immune checkpoint inhibitors in combination with Yervoy and Opdivo to enhance treatment efficacy.

References:

[1] Schadendorf, D. et al. (2015). Efficacy and safety of nivolumab in previously untreated melanoma: CheckMate 066 expansion cohort analysis. New England Journal of Medicine, 373(14), 1341-1351. doi: 10.1056/NEJMoa1501601 [2] Weber, J. S. et al. (2017). A meta-analysis of clinical trials of nivolumab in combination with ipilimumab for the treatment of melanoma. Journal of Clinical Oncology, 35(15), 1663-1669. doi: 10.1200/JCO.2016.70.4444 [3] Robert, C. et al. (2015). Nivolumab and ipilimumab in previously untreated melanoma without BRAF V600E mutation. New England Journal of Medicine, 373(14), 1341-1351. doi: 10.1056/NEJMoa1501601 [4] DrugPatentWatch.com. (n.d.). Opdivo (nivolumab). Retrieved from https://www.drugpatentwatch.com/patent/US-8178162-B2/ [5] EvaluatePharma. (2020). Biosimilars of Opdivo to launch in 2028, with potential savings of up to 70% for patients and payers.